Researchers uncovered an RNA‑guided mechanism by which STAT3 signaling shapes CD4+ T helper cell differentiation in non‑small cell lung cancer (NSCLC), elucidating epigenetic and epitranscriptomic changes that alter anti‑tumor immunity. The study detailed how RNA interactions modulate STAT3 activity, shifting T‑cell phenotypes within the tumor microenvironment. Findings, published by a multidisciplinary team, point to STAT3 and its RNA regulators as potential targets to reprogram tumor‑infiltrating CD4+ cells and enhance immunotherapy responses. The mechanistic insights give translational researchers concrete molecular targets for combination strategies with checkpoint inhibitors or adoptive cell therapies.